Tuesday, the FDA said it received reports of patients developing T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment...
Benzinga - by Benzinga Insights, Benzinga Staff Writer. Gilead Sciences's (NYSE:GILD) short percent of float has fallen 4.37% since its last report. The company recently reported...
Benzinga - by Benzinga Insights, Benzinga Staff Writer. Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 4.81% on an annualized basis producing...
Shares of Aurinia Pharmaceuticals (NASDAQ: NASDAQ:AUPH) saw a notable increase today, rising by 6.7% amid speculation about a potential acquisition by Gilead Sciences...
Benzinga - by Benzinga Insights, Benzinga Staff Writer. In today's rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts...
Investing.com -- The Dow closed lower Thursday, as Federal Reserve chairman Jerome Powell dealt a blow to bets on sooner rather later rate cuts after signaling that the Fed isn't...
Investing.com -- U.S. stocks were wobbling on Wednesday amid a slew of earnings reports, as investors await a second public appearance this week by Federal Reserve Chair Jerome...
Kite, a Gilead Company (GILD), and Arcellx, Inc. (ACLX), today announced that the companies have expanded their existing collaboration, which was originally announced in December...
Kite, a unit of Gilead Sciences (GILD),has announced that theFDA has granted approval for its T cell immunotherapy Yescarta (axicabtagene ciloleucel) for a certain category of adults...
1
Up Again
0
Time to load up before the big rise coming next week
3
Classic pump n’ dump. What a shambles
1
Will reach above 95
5
when? hahah
0
Good time to accumulate.
1
Gilead will be supplying remdesivir to 127 countries starting next week! Also backed by big government organisations including donald trump. Good investmenr
2
High chance to be trading above 90, good long stock
4
By Deena Beasley(Reuters) - More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc., according to new data based on patient observation.The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included -- in one case because of a dosing error.